Post by Medical Device Network

Stryker is maintaining its 2026 outlook despite its Q1 performance being impacted by a cyberattack that caused disruption across the company’s operations in March. The medtech giant reported revenues above $6bn for Q1, indicative of a 2.6% year-over-year (YoY) uptick from around $5.8bn. Despite the steady YoY performance, Stryker’s revenue fell short of analysts’ expectations of $6.35bn, according to data ​compiled by the London Stock Exchange Group (LSEG) and seen by Reuters. Stryker’s chief finance officer, Preston Wells, revealed during an earnings call that Q1’s adjusted earnings per share (EPS) of $2.60 was “minus 8.5%” YoY. Nonetheless, Stryker has opted to maintain its previously outlined 2026 growth expectations of between 8% to 9.5% and still expects earnings to fall in the $14.90-$15.10 per share range. Reflecting further on the EPS drop-off, Wells told investors the decline was driven by “limited sales growth and lost manufacturing absorption” related to the cyber incident, as well as tariffs and increased interest expense that were “partially offset” by the company’s “ongoing focus on operational excellence and a slightly favourable impact from foreign currency translation”. #medtech #cyber #healthcarefinances Read the full report below: https://lnkd.in/e_zSb7Mc